Hypertension (HTN) in National Cancer Institute of Canada Clinical Trials Group study BR.24: A randomized, double-blind phase II trial of carboplatin (C) and paclitaxel (P) with either daily oral cediranib (CED), an inhibitor of vascular endothelial growth factor receptors, or placebo, in patients with advanced non-small cell lung cancer Conferences uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Goodwin, RA
  • Seymour, L
  • Ding, K
  • Gauthier, I
  • Le Maitre, A
  • Frymire, E
  • Arnold, Andrew
  • Shepherd, FA
  • Goss, GD
  • Laurie, SA

publication date

  • May 20, 2009